Renée Galá
Member of the Audit Committee
Member of the Compensation Committee
Board member since 2025
Ms. Galá's executive leadership at global companies in the healthcare industry, including her strategic operating expertise as chief executive officer and chief operating officer, and financial expertise as a chief financial officer, provide valuable strategic, operating, financial and accounting experience to the Dexcom Board.
Career Highlights:
- Current President and Chief Executive Officer of Jazz Pharmaceuticals PLC, a global biopharmaceutical company, since August 2025
- President and Chief Operating Officer of Jazz from 2023 to 2025 overseeing the company’s global business operations, as well as corporate strategy.
- Executive Vice President and Chief Financial Officer of Jazz from 2020 to 2023, responsible for company’s financial operations, corporate strategy and corporate development.
- Chief Financial Officer of GRAIL, Inc., a private healthcare company focused on the early detection of cancer, from January to June 2019
- Senior Vice President and Chief Financial Officer of Theravance Biopharma, Inc. from December 2014 to January 2019
Key Experience and Qualifications:
- Executive leadership experience with oversight of corporate strategy and global operations
- Public company financial leadership in the life sciences industry
Other Directorships - Current:
- Jazz Pharmaceuticals PLC
Other Professional Experience and Community Involvement:
- Previous member of the board of directors at:
- Gossamer Bio, Inc., where she chaired the audit committee, from 2018 to 2024
- Gyroscope Therapeutics from 2020 to 2021
- Concept Therapeutics, Inc. from 2016 to 2019
Education:
- B.S. in Mathematics from Vanderbilt University
- MBA from Columbia Business School